RedHill Biopharma Receives $1.1M in Talicia Licensing Payments

TL;DR

RHBP snagged $1.1M for Talicia licensing, good news for cash flow.

AI Summary

RedHill Biopharma Ltd. announced on August 18, 2025, that it received licensing payments totaling $1.1 million for its Talicia® drug. This filing incorporates by reference a press release detailing these payments.

Why It Matters

This influx of capital provides RedHill Biopharma with additional resources to fund its operations and potential future development of Talicia®.

Risk Assessment

Risk Level: low — The filing is a routine report of licensing payments and does not introduce new material risks.

Key Numbers

• $1.1M — Licensing Payments (Received for Talicia®)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• Talicia® (product) — Drug for which licensing payments were received
• $1.1 million (dollar_amount) — Total licensing payments received
• August 2025 (date) — Reporting period for the press release

FAQ

Key Financial Figures

• $1.1 Million — ved Talicia Licensing Payments Totaling $1.1 Million". This Form 6-K is hereby incorporated
• $1.1 m — royalties and other payments, totaling $1.1 million, following the first ex-U.S. comm
• $1.1 million — d other payments totaling approximately $1.1 million. "The presence of H. pylori infection

Filing Documents

• zk2533670.htm (6-K) — 46KB
• image00001.jpg (GRAPHIC) — 308KB
• 0001178913-25-002958.txt ( ) — 472KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: August 18, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Received Talicia Licensing Payments Totaling $1.1 Million RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S. commercial launch of Talicia in 2024 -- Talicia is the first FDA-approved rifabutin-based product specifically designed to treat Helicobacter pylori (H. pylori), a bacterial infection with high and rising resistance rates that affects over 50% of the world's adult population 1 and is the strongest risk factor for gastric cancer and peptic ulcer disease -- Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists 2 for treatment of H. pylori infection and was granted a Qualified Infectious Disease Product (QIDP) designation by the FDA, providing eligibility for a total of eight years of U.S. market exclusivity; Talicia is patent protected through 2042 RALEIGH, N.C., August 18, 2025, RedHill Biopharma Ltd. (Nasdaq: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received its first Talicia 3 ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1 million. "The presence of H. pylori infection is the strongest risk factor for gastric cancer and peptic ulcer disease and there is a significant global medical need for a highly effective first-line H. pylori therapy," said Rick Scruggs, President, RedHill Biopharma Inc. & Chief Commercial Officer . " H. pylori is a major public health concern, with over 50% of the world's adult population infected. Talicia offers the best hop

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-stu

View Full Filing

View this 6-K filing on SEC EDGAR